key: cord-0932835-p66z1fr9
authors: Hamed Azzam, Shirin; Hamed, Mira; Mukari, Abed
title: COVID‐19 vaccine in patients with dermal hyaluronic acid fillers in the tear trough: A retrospective study
date: 2022-03-07
journal: J Cosmet Dermatol
DOI: 10.1111/jocd.14875
sha: e1411b91021b1e48c906323f19ea26563b0bda6c
doc_id: 932835
cord_uid: p66z1fr9

nan

To the Editor, COVID-19 has affected the entire world since its onset in 2020.

Recently, concerns have raised regarding potential hypersensitivity reactions of previously placed HA dermal fillers with COVID-19 vaccines. The Moderna mRNA-1273 vaccine trial reported an incidence rate of facial swelling of 0.02% after receiving the vaccine. 1 We conducted a retrospective study that aimed to assess the incidence of adverse events related to COVID-19 vaccines.

All included patients had received two doses of Pfizer/BioNTech COVID-19 vaccine (US) (interval of 21-28 days) and had been previously injected with dermal fillers in the tear trough area, from January 2020 to January 2021. This study adhered to the principles of the Declaration of Helsinki.

Forty-one participants were included in the study. Table 1 The patient was previously injected in the tear trough area with Juvederm Volite (Allergan Inc.). 2 In our case series, only one patient suffered from pain in a previous uneventful injected tear trough area. There was no swelling, nodules, or erythema. Therefore, according to the DIR definition, this pain did not qualify. 4 The precise mechanism of pain is not clearly understood; therefore, there is a need for more data to be collected regarding any association be- Previous literature published a frequency of 11.6% and 0.9% of transient edema or inflammation and severe edema, respectively, following tear trough filler injections independent from vaccination. 6 Therefore, according to the data from this retrospective study and due to the increasing morbidity and mortality of the COVID-19 pandemic, vaccination should not be discouraged in a patient with previous dermal filler injected tear trough. Furthermore, as more people receive the third dose of the vaccine worldwide, more data will be available regarding the connection, if any, between dermal filler and COVID-19 vaccine.

Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs

Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccinatin-A case report

Hypersensitivity reaction to hyaluronic acid dermal filler following novel coronavirus infection-a case report

Delayed inflammatory reactions to hyaluronic acid fillers: a literature review and proposed treatment algorithm

Global recommendations on covid-19 vaccines and soft tissue filler reactions: a survey-based investigation in cooperation with the international society for dermatology and aesthetic surgery (ISDS)

Recommendations for the treatment of tear trough deformity with cross-linked hyaluronic acid filler

https://orcid.org/0000-0002-5642-6508